Abstract 143P
Background
Human leukocyte antigen-G (HLA-G), a tolerogenic protein usually restricted to the placenta, is upregulated by many solid cancers where it promotes tumour immune evasion by engaging inhibitory receptors immunoglobin-like transcript (ILT)2 and ILT4 on lymphoid and myeloid cells.UCB4594, a humanized afucosylated IgG1 HLA-G antibody, was developed to promote therapeutic tumour immune rejection by blocking interaction of HLA-G with ILT2 and ILT4 as well as direct induction of tumour cell death via natural killer (NK) cells, macrophages and complement.
Methods
Functional properties of UCB4594 were evaluated using a suite of in vitro assays including assessment of NK cell killing, complement dependent lysis, and antibody-dependent cellular phagocytosis (ADCP) of tumour targets. To further support its therapeutic potential, UCB4594-induced tumour cell killing dependent on tumour infiltrating immune cells was evaluated in 20 primary solid human tumours (10 renal and 10 colorectal) using an ex-vivo human tumoroid platform.
Results
UCB4594 exhibited strong affinity for HLA-G (4-6 nM for soluble HLA-G; <0.025 nM for cell expressed HLA-G), and high selectivity (no binding to other HLA-I molecules on transfected cells or human CD4 T-cells from 60 donors). UCB4594 effectively disrupted interaction of HLA-G with ILT2 and ILT4. UCB4594 induced NK cell killing of 85% and 40% of HLA-G transfected HCT116 cells and naturally HLA-G expressing JEG3 cells, respectively and activated potent complement-dependent lysis of HLA-G expressing Reh cells. UCB4594's dual mechanisms promoting phagocytosis are driven by Fc receptor-mediated ADCP and HLA-G receptor blocking (depletion of 22.0±10.8% of target cells at 0.1 μg/mL and 44.8±8.6% at 10 μg/mL), activity that was enhanced in the presence of anti-CD47. Across 20 human tumours, UCB4594 IgG1 led to 1.5-fold higher tumour cell death than the isotype control in 9 tumours, seen at 24h/72h post-treatment.
Conclusions
These findings support the development of UCB4594 as a novel cancer immunotherapy for application in several solid tumour indications.
Editorial acknowledgement
Medical writing support for this abstract was provided by Enago Life Sciences, India.
Legal entity responsible for the study
UCB Pharma.
Funding
UCB Pharma.
Disclosure
A.L. White, R. McElhone, G. Le Friec, T. Colley, V. O’Dowd: Financial Interests, Personal, Full or part-time Employment: UCB Pharma. C. Thompson, C. Berteau: Financial Interests, Personal, Full or part-time Employment: UCB Pharma; Financial Interests, Personal, Stocks/Shares: UCB Pharma.
Resources from the same session
14P - Integrated modelling of T cell repertoires to identify clonotype signatures of ICI response
Presenter: Juan Luis Melero
Session: Poster Display
16P - Exosomal PD-L1 and lactate predict clinical outcomes of PD-1 blockade combined with chemotherapy in advanced-stage gastric and gastroesophageal junction adenocarcinoma
Presenter: Yongshun Chen
Session: Poster Display
17P - Spatial Characteristics Associated with the Chemo and Immuno-treatment Response of Gastric Cancer Revealed by Multi-omics Analysis
Presenter: Gang Che
Session: Poster Display
18P - Association of DNA methylation profiles with pathologic complete response in early triple negative breast cancer patients receiving neoadjuvant chemoimmunotherapy
Presenter: Angelika Starzer
Session: Poster Display
19P - The prognostic value of soluble CD73 in advanced triple-negative breast cancer: an exploratory analysis of the SYNERGY trial
Presenter: Denis Zoë
Session: Poster Display
21P - Mass cytometry reveals a population of exhausted CD8+ T cells associated with durvalumab/tremelimumab/vinorelbine efficacy in advanced cervical cancer (iMOVIE).
Presenter: Alexandre Bertucci
Session: Poster Display
22P - Predictive value of Tertiary Lymphoid Structure in patients with mismatch repair deficient advanced/ recurrent endometrial cancer treated with Dostarlimab.
Presenter: Maria Kfoury
Session: Poster Display
23P - Circulating immune cells and activity of immune checkpoint inhibitors in metastatic renal cell carcinoma
Presenter: Ronan Flippot
Session: Poster Display
24P - Chromosome 3p-related gene alterations (GA) as biomarkers for immunocombinations in metastatic renal cell carcinoma (mRCC): a hypothesis-generating analysis
Presenter: Matteo Rosellini
Session: Poster Display